ClinicalTrials.gg
RecruitingNCT06775340Updated May 13, 2025

Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

A Phase 2 interventional study of RSS0343 Tabella in Adolescent Asthma, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 6 under way, 2 of them phase 3. Asthma · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
4th of 15
252 · median 84
Started
2025
with 3 others
Phase 2
6 of 15
3 open now
Registered
11th of 15
by date

Among the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., this one is the 4th largest by planned enrollment, is one of 4 that started in 2025, is one of 6 in phase 2, and was the 11th registered.

Asthma

4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

Studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of RSS0343 tablets in patients with non-cystic fibrosis bronchiectasis

03

Conditions studied

  • Adolescent Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years old (including boundary values), male and female.
  2. Female subjects weigh ≥45 kg and male subjects weigh ≥50 kg.
  3. HRCT shows bronchiectasis affecting one or more lobes of the lung and is confirmed by the clinician as NCFB.
  4. The expected survival is greater than 12 months.
  5. was signed before the trial.
  6. Potentially fertile subjects voluntarily take appropriate measures.

Exclusion criteria

Exclusion Criteria:

  1. Patients with pulmonary hypertension or (COPD) or asthma as determined by the investigators were the primary diagnosis were screened.
  2. An active, symptomatic infection caused by respiratory viruses, including COVID-19, influenza viruses, etc.
  3. Have psoriasis or lichen planus.
  4. Have Wright's disease/keratosis or hemorrhagic keratosis, or reactive arthritis.
  5. Have chlorine acne, large common warts, or keratodermatitis.
  6. Has diabetic foot.
  7. Have periodontal disease, oral infection, or loose teeth.
  8. History of malignant tumor within 5 years prior to screening.
  9. Screening subjects with a history of liver disease or currently receiving treatment for liver disease, including but not limited to acute or chronic hepatitis, cirrhosis, or liver failure.
  10. Researchers consider any other unstable clinical disease.
  11. Oral or inhaled antibiotics were received 4 weeks prior to first administration.
  12. were administered 4 weeks before the first dose.
  13. Received drugs within 4 weeks prior to screening that may cause hyperkeratosis of the skin.
  14. Received within 30 days prior to initial administration.
  15. Participated in clinical trials of any medical device within 3 months prior to screening.
  16. Active virus infection, active virus infection, or known infection or known syphilis infection.
  17. Drug abusers.
  18. Current smoker or former smoker for less than 3 months.
  19. Suspected allergy to the product or any component of the investigational product, or severe allergy to any drug, food, toxin or other exposure.
  20. Pregnant or lactating women.
  21. The subjects were unable to complete the questionnaires due to their limited educational level, or neither the subjects themselves nor their families could fill in the subject log card.
  22. The researchers determined that there were other circumstances that were not suitable for participation in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
252 participants (estimated)

Study arms

  • Experimental
    RSS0343 Tabella

    Drug: RSS0343 Tabella

Interventions

06

What researchers measure

Primary outcomes

  1. The number of occurrences of AEs

    Time frame: Day 1 to Day56

  2. the frequency of occurrence of AEs

    Time frame: Day 1 to Day56

Secondary outcomes

  1. RSS0343 amount of tablets of their metabolites in the blood

    Time frame: Day7, Day14, Day21, Day 28

  2. Changes in the concentrations of active neutrophil elastase (NE) in sputum

    Time frame: Day7, Day14, Day21, Day 28, Day 56

  3. Changes in the concentrations of cathepsin G (CatG) in sputum

    Time frame: Day7, Day14, Day21, Day 28, Day 56

  4. Changes in the concentrations of enzyme protease 3 (PR3) in sputum

    Time frame: Day7, Day14, Day21, Day 28, Day 56

07

Study locations

1 of 1 sites recruiting
  • First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510140, China
    Recruiting
    • Weijie Guan · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Nov 2027, 34 months after the start.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 34 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 15, 2025
StartActual
Jan 22, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Dec 2027
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06775340
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Jan 22, 2025
Primary completion
Nov 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 13, 2025

Study contacts

Zi Lin
Contact
zi.lin.zl30@hengrui.com
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RSS0343

Start the discussion